Success Metrics

Clinical Success Rate
89.7%

Based on 366 completed trials

Completion Rate
90%(366/408)
Active Trials
21(4%)
Results Posted
38%(140 trials)
Terminated
42(8%)

Phase Distribution

Ph phase_4
139
27%
Ph not_applicable
49
9%
Ph early_phase_1
6
1%
Ph phase_3
121
23%
Ph phase_2
102
20%
Ph phase_1
90
17%

Phase Distribution

96

Early Stage

102

Mid Stage

260

Late Stage

Phase Distribution507 total trials
Early Phase 1First-in-human
6(1.2%)
Phase 1Safety & dosage
90(17.8%)
Phase 2Efficacy & side effects
102(20.1%)
Phase 3Large-scale testing
121(23.9%)
Phase 4Post-market surveillance
139(27.4%)
N/ANon-phased studies
49(9.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.5%

366 of 423 finished

Non-Completion Rate

13.5%

57 ended early

Currently Active

21

trials recruiting

Total Trials

520

all time

Status Distribution
Active(30)
Completed(366)
Terminated(57)
Other(67)

Detailed Status

Completed366
unknown66
Terminated42
Withdrawn15
Recruiting14
Not yet recruiting8

Development Timeline

Analytics

Development Status

Total Trials
520
Active
21
Success Rate
89.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (1.2%)
Phase 190 (17.8%)
Phase 2102 (20.1%)
Phase 3121 (23.9%)
Phase 4139 (27.4%)
N/A49 (9.7%)

Trials by Status

active_not_recruiting71%
enrolling_by_invitation10%
terminated428%
completed36670%
recruiting143%
not_yet_recruiting82%
withdrawn153%
unknown6613%
suspended10%

Recent Activity

Clinical Trials (520)

Showing 20 of 520 trialsScroll for more
NCT03560882Phase 1

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

Active Not Recruiting
NCT03819101Phase 3

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Recruiting
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT06312748Phase 1

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

Recruiting
NCT05342974Early Phase 1

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

Completed
NCT07534592Phase 1

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

Not Yet Recruiting
NCT07530289Phase 1

A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018)

Not Yet Recruiting
NCT06372925Phase 4

Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction

Recruiting
NCT05483010Phase 2

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

Recruiting
NCT07502001Phase 1

Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin

Not Yet Recruiting
NCT07497776Phase 4

Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome

Completed
NCT05488067Phase 4

Atorvastatin Therapy on Xanthoma in Alagille Syndrome

Completed
NCT02432534Phase 2

Atorvastatin in Active Vitiligo

Completed
NCT07474649Phase 3

A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

Not Yet Recruiting
NCT07045142Phase 3

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients

Recruiting
NCT06157099Phase 2

Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma

Active Not Recruiting
NCT07462715Phase 4

Statins Against Bushfire Smoke

Not Yet Recruiting
NCT04915183Phase 2

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Recruiting
NCT06686615

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Recruiting
NCT07268625Phase 1

Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin

Completed

Drug Details

Intervention Type
DRUG
Total Trials
520